Antivitaminiques K, anticoagulants oraux directs : où est la vérité ?
| Autor: | J.-F. Schved, J.-P. Laroche |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Industrial communication Antivitamine k business.industry medicine.drug_class 030204 cardiovascular system & hematology Vitamin k Vitamin K antagonist Surgery Clinical trial 03 medical and health sciences 0302 clinical medicine medicine 030212 general & internal medicine Cardiology and Cardiovascular Medicine Intensive care medicine business |
| Zdroj: | Journal des Maladies Vasculaires. 41:383-388 |
| ISSN: | 0398-0499 |
| Popis: | Vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) are now in competition. The companies are trying to replace VKA by DOACs, totally or at least greatly VKA should VKA disappear in favor of DOACs? There are still many questions about DOACs. The purpose of this article is to make a well-considered decision in this area. The aim is not to denigrate one or the other but to share things between these two families of anticoagulants. Physicians using these drugs must have a full knowledge about compared efficacy and safety. We feel necessary to increase distance between effective results of the clinical trials and industrial communication around DOACs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect